Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Sep 11;19:107. doi: 10.1186/s13058-017-0896-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2017

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 5 — Visual predictive check (VPC) of platinum adducts observed (dots) and predicted (shaded area shows 95% CI prediction interval and the straight line the typical pharmacokinetic profile) in peripheral blood mononuclear cells (PBMCs) from patients stratified for treatment with single agent (a) at day 1 (left) and combined with a poly(ADP-ribose) polymerase inhibitor (PARPi) (talazoparib (right)), suggesting that platinum adduct formation was not influenced by the PARPi. b VPC stratified for gBRCA patients and non-carriers, showing the results for two individuals. These plots suggest that lower carboplatin adduct formation was observed in patients with BRCA 1/2 mutations (left) compared to non-carriers (right)